Pazufloxacin

Pazufloxacin Report

Name: Pazufloxacin Name (English): Pazufloxacin DrugBank ID: DB11774 Type: Small Molecule CAS Number: 127045-41-4

Molecular Formula: $\mathrm{C}{16} \mathrm{H}{15} \mathrm{FN}{2} \mathrm{O}{4}$ Molecular Weight: 318.304 g/mol

Synonyms:

• T-3761
• (3S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
• (S)-10-(1-Aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
• 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-
• Pazufloxacine
• Pazufloxacino

Pharmacology: Pazufloxacin is a fluoroquinolone antibiotic. It inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and transcription. It demonstrates broad-spectrum antibacterial activity against Gram-negative and some Gram-positive bacteria, including strains resistant to cephalosporins, carbapenems, and aminoglycosides.

Indications: Pazufloxacin is marketed in some regions for the treatment of various bacterial infections, including respiratory and urinary tract infections. Clinical trials have also investigated its use in bacterial conjunctivitis.

Pharmacokinetics: Pazufloxacin exhibits good oral bioavailability and tissue penetration. It is mainly excreted in urine and has a short half-life (2-2.5 hours).

Drug Interactions: Pazufloxacin has the potential for numerous drug interactions. Examples include increased risk of QTc prolongation with certain medications, altered efficacy of antidiabetic agents, increased neuroexcitatory activities with NSAIDs, and decreased absorption with antacids containing aluminum or magnesium. It can also affect the metabolism of various drugs.